For me, DNDN is a huge reason for this recent decline and PRR faliing to turn the Dubai opportunity into profit is the nail in the coffin for me.
DNDN shows that even if PRR had successful Phase 3 trials and FDA approval it is no guarntee to become profitable. They're not profitable (nor will be any time soon) and they've got a huge head start on PRR. Dubai is proof the PRR has the same cost issues.
CVac probably works but sadly that doesn't guarantee a successful business.
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
25.5¢ |
Change
-0.005(1.92%) |
Mkt cap ! $372.3M | |||
| Open | High | Low | Value | Volume |
| 26.0¢ | 27.5¢ | 25.5¢ | $1.276M | 4.866M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 4 | 22343 | 25.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 26.0¢ | 193000 | 3 |
View Market Depth
| Last trade - 16.10pm 21/07/2025 (20 minute delay) ? |
| IMM (ASX) Chart |